文献速递心力衰竭与心肌病

VICTORIA研究:射血分数降低心衰患者的血红蛋白与临床结局

Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA).
PubMed 文献 · Circulation · 2021-08-25

VICTORIA试验事后分析探讨维利西呱对血红蛋白的影响及其与疗效的关系。基线35.7%患者存在WHO贫血,维利西呱组16周内贫血发生率高于安慰剂组(P<0.001),但16周后血红蛋白不再下降。血红蛋白水平与维利西呱的治疗获益无关。

要点

  • 基线贫血常见(35.7%),低血红蛋白与临床事件风险增加相关。
  • 维利西呱组16周内贫血发生率高于安慰剂组,但16周后血红蛋白稳定。
  • 血红蛋白水平不影响维利西呱对主要结局的治疗获益。

核心结论

  • 贫血在随机化时常见,低血红蛋白与临床事件频率更高相关。
  • 维利西呱在16周时轻度降低血红蛋白,但该效应未进一步进展,且与维利西呱的治疗获益无关。

研究设计与样本

  • VICTORIA试验的事后分析,纳入射血分数降低的心力衰竭患者。
  • 评估维利西呱与随机化时血红蛋白、贫血发生及基线血红蛋白与治疗获益的关系。

主要发现

  • 基线时1719例(35.7%)患者存在WHO定义的贫血,中位血红蛋白13.4 g/dL(25th, 75th百分位:12.1, 14.7 g/dL)。
  • 随机化后16周,1643例患者存在WHO贫血(维利西呱组新增284例,安慰剂组新增219例),维利西呱组发生率更高(P<0.001)。
  • 16周后至96周随访期间血红蛋白未进一步下降,血红蛋白/血细胞比容比值保持恒定。
  • 总体不良事件贫血发生于342例患者(7.1%)。
  • 较低血红蛋白与维利西呱(对比安慰剂)对主要结局的治疗获益无关。

关键数值与推荐

  • 贫血定义:男性血红蛋白<13.0 g/dL,女性<12.0 g/dL(WHO标准)。
  • 主要结局:心血管死亡或心力衰竭住院的复合终点。

临床怎么用

  • 心衰合并贫血患者使用维利西呱时,应关注血红蛋白变化,但16周后趋于稳定。
  • 基线血红蛋白水平不应影响维利西呱的治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the VICTORIA trial (Vericiguat Global Study in Patients with Heart Failure with Reduced Ejection Fraction), anemia occurred more often in patients treated with vericiguat (7.6%) than with placebo (5.7%). We explored the association between vericiguat, randomization hemoglobin, development of anemia, and whether the benefit of vericiguat related to baseline hemoglobin. METHODS: Anemia was defined as hemoglobin <13.0 g/dL in men and <12.0 g/dL in women (World Health Organization Anemia). Adverse events reported as anemia were also evaluated. We assessed the risk-adjusted relationship between hemoglobin and hematocrit with the primary outcome (composite of cardiovascular death or heart failure hospitalization) and the time-updated hemoglobin relationship to outcomes. RESULTS: At baseline, 1719 (35.7%) patients had World Health Organization anemia; median hemoglobin was 13.4 g/L (25th, 75th percentile: 12.1, 14.7 g/dL). At 16 weeks from randomization, 1643 patients had World Health Organization anemia (284 new for vericiguat and 219 for placebo), which occurred more often with vericiguat than placebo (P<0.001). After 16 weeks, no further decline in hemoglobin occurred over 96 weeks of follow-up and the ratio of hemoglobin/hematocrit remained constant. Overall, adverse event anemia occurred in 342 patients (7.1%). A lower hemoglobin was unrelated to the treatment benefit of vericiguat (versus placebo) on the primary outcome. In addition, analysis of time-updated hemoglobin revealed no association with the treatment effect of vericiguat (versus placebo) on the primary outcome. CONCLUSIONS: Anemia was common at randomization and lower hemoglobin was associated with a greater frequency of clinical events. Although vericiguat modestly lowered hemoglobin by 16 weeks, this effect did not further progress nor was it related to the treatment benefit of vericiguat. Registration: URL: https://www.clinicaltrials.gov: Unique identifier: NCT02861534.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Ezekowitz JA, Zheng Y, Cohen-Solal A, et al. Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). Circulation. 2021. PMID: 34432985. doi:10.1161/CIRCULATIONAHA.121.056797

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。